Mayo Comprehensive Cancer Center Grant

梅奥诊所癌症中心（MCCC）是梅奥诊所/梅奥医学院的矩阵中心。该中心由428名成员组成（自2003年以来净增加了97名新成员），来自3个地理站点的55个部门（罗切斯特，MN - MCR；杰克逊维尔，FL - MCF；凤凰城/斯科茨代尔，AZ - MCA）。MCCC的目标是在今天提供最好的癌症治疗，同时为明天制定改进的策略，为美国和世界各地的癌症患者服务。MCCC有12个研究项目：妇女癌症；胃肠道癌症;前列腺癌;血液恶性肿瘤;Neuro-oncology;癌症成像;细胞生物学;发展治疗;免疫学及免疫治疗；基因与病毒治疗；遗传流行病学与风险评估；癌症预防与控制。15个共享资源：调查研究、药学、生物统计学、生物信息学、组织与细胞分子分析、生物标本采集与处理、临床研究室；转基因与基因靶向小鼠共享资源，蛋白质化学与蛋白质组学，流式细胞术/光学形态学，电子显微镜，药理学，基因与病毒治疗，细胞遗传学，基因分析。自上次更新以来，MCCC继续增长，同行评审的总资金从7760万美元增加到1.058亿美元，NCI的资金从5630万美元增加到7570万美元。特别值得注意的是，除了增加研究者发起的拨款外，MCCC还增加了2个新的孢子（乳房和大脑）和2个新的培训拨款。此外，还有其他4个孢子（淋巴瘤，前列腺癌，多发性骨髓瘤，胰腺），以及几个多学科（P01, N01, 2个u01和2个u10）和4个培训资助的竞争性更新。在此期间，年度出版物增加了28%，特别是具有高影响力的临床和科学出版物，这证明了研究生产力。自上次竞争性更新以来，MCCC受益于：1)新设施，新实验室空间净增加（100万平方英尺）以及新的住院/门诊空间；2)增加机构承诺：a) 11个新的捐赠教授职位（2200万美元的机构/ 2200万美元的慈善），b) 15个新教师的工资/启动资金，c)加强MCCC在3个站点的整合的资金（760万美元），d)在MCA和MCF的临床试验中增加服务不足的少数民族的累积资金（5年1300万美元）。在过去的五年里，CCSG的发展基金被用来帮助这三个校区的教师招聘。在接下来的5年里，我们计划扩大遗传学、肺癌和黑色素瘤的研究。

The Mayo Clinic Cancer Center (MCCC) is a matrix center within the Mayo Clinic / Mayo Medical School. The Center is made up of 428 members (net increase of 97 new members since 2003) from 55 departments based at 3 geographical sites (Rochester, MN - MCR; Jacksonville, FL - MCF; and Phoenix/Scottsdale, AZ - MCA). The goal of the MCCC is to provide the best cancer care today, while developing improved strategies for tomorrow, serving cancer patients throughout the U.S. and the world. MCCC has 12 research programs: Women's Cancer; Gastrointestinal Cancer; Prostate Cancer; Hematologic Malignancies; Neuro-oncology; Cancer Imaging; Cell Biology; Developmental Therapeutics; Immunology & Immunotherapy; Gene & Virus Therapy; Genetic Epidemiology & Risk Assessment; Cancer Prevention & Control. Research is facilitated by 15 shared resources: Survey Research, Pharmacy, Biostatistics, Bioinformatics, Tissue & Cell Molecular Analysis, Biospecimens Accessioning & Processing, Clinical Research Office; Transgenic & Gene Targeted Mouse Shared Resource, Protein Chemistry & Proteomics, Flow Cytometry/Optical Morphology, Electron Microscopy, Pharmacology, Gene & Virus Therapy, Cytogenetics, and Gene Analysis. Since the last renewal, MCCC has continued to grow with an increase in overall peer-reviewed funding from $77.6 million to $105.8 million and an increase in NCI funding from $56.3 million to $75.7 million. Of particular note is that, in addition to an increase in investigator-initiated grants, MCCC has 2 new SPOREs (Breast and Brain) and 2 new training grants. Furthermore, there has been successful competitive renewal of 4 other SPOREs (Lymphoma, Prostate, Multiple Myeloma, Pancreas), as well as several multidisciplinary (P01, N01, 2 U01s, and 2 U10s) and 4 training grants. Research productivity is demonstrated by a 28% increase in annual publications during this period, particularly high impact clinical and scientific publications. Since the last competitive renewal, MCCC has benefited from: 1) new facilities with a net increase in new lab space (>100,000 sq ft) as well as new inpatient / outpatient space; 2) increased institutional commitment with a) 11 new endowed professorships ($22M institutional / $22M philanthropic), b) salary/start-up funds for 15 new faculty, c) funds to enhance integration of MCCC across 3 sites ($7.6M), and d) funds to enhance accrual of underserved minorities to clinical trials at MCA and MCF ($13M over 5 years). During the past 5 years, Developmental Funds from CCSG have been leveraged to aid in faculty recruitment at each of the 3 sites. During the next 5 years, we have plans to expand genetics, lung cancer, and melanoma research.